Baxter Clears Hurdle On Road To Resuming Infusion Pump Sales
This article was originally published in The Gray Sheet
Executive Summary
FDA cleared modifications to Baxter Healthcare's trouble-prone Colleague infusion pump Feb. 27, allowing the company to start upgrading defective versions of the device in U.S. hospitals within months
You may also be interested in...
Baxter’s Relaunch Of Recalled Infusion Pump Will Add $75 Mil. In ’08 Sales
Baxter expects a mid-year U.S. relaunch of previously recalled Colleague infusion pumps to generate $75 million in sales in 2008
Baxter’s Relaunch Of Recalled Infusion Pump Will Add $75 Mil. In ’08 Sales
Baxter expects a mid-year U.S. relaunch of previously recalled Colleague infusion pumps to generate $75 million in sales in 2008
Another Class I Correction Needed On Baxter Infusion Pumps
A recall initiated last month by Baxter removing 4,500 upgraded versions of its triple-channel Colleague infusion pumps from use was designated Class I by FDA July 18